It is not FDA-approved and may not meet the same standards as the approved drugs (Mounjaro, Zepbound)
Evolving Peptide Therapy: Safety and Evidence First As peptide therapy continues to evolve, the focus remains on: Safety: Understanding short- and long-term risk profiles Regulatory compliance: Using peptides that fit within current FDA and compounding regulations Scientific support: Prioritizing treatments backed by clinical data, not just anecdotal reports Individualization: Matching each patients treatment plan to their medical history, goals, and risk tolerance Potential Alternatives to Ipamorelin and CJC-1295: Tesamorelin and Hexarelin Tesamorelin and Hexarelin illustrate how newer or alternative peptides can help fill the gap left by Ipamorelin and CJC-1295
People who take GLP-1s report not feeling hungry, not ruminating about food, needing to eat less to feel full, and in general, losing weight without effort
A study published in the Journal of Clinical Endocrinology & Metabolism showed that Sermorelin administration can increase lean body mass and reduce body fat
That might be an appropriate deficit for a non-breastfeeding woman pursuing weight loss